13 results about "Anti hbv" patented technology

Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and / or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and / or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.

The present invention provides anti-HBV compounds, pharmaceutically acceptable compounds or stereoisomers thereof, and preparation methods and uses for treating, eradicating or inhibiting HBV infection or for alleviating liver injury caused by HBV infection, and so on.

The application discloses a dehydrocostus lactone derivative, a preparation method and medical application thereof, and belongs to the technical field of chemical synthesis. The dehydrocostus lactone derivative is shown as a general formula I. The compound has certain inhibiting effect on HBsAg and HBeAg, can be used for preparing anti-HBV drugs, and provides more efficient and safe candidate drug molecules for clinical anti-HBV treatment.

The present invention relates to an antibody against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the antibody, and a pharmaceutical composition comprising the antibody. The anti-HBsAg antibody disclosed by the invention can be combined with HBsAg in a pH-dependent manner, and has enhanced capability of combining with FcRn and Fc gamma R, remarkably enhanced antigen removal effect and prolonged half-life period.

The invention discloses application of a host factor RAB10 in regulation and control of hepatitis B virus antigen expression and anti-hepatitis B virus. The invention provides an application of a host factor RAB10 or a coding gene thereof in regulation and control of hepatitis B virus replication or hepatitis B virus antigen expression level in host cells, and an application of the host factor RAB10 or an expression promoter thereof in preparation of drugs for resisting hepatitis B virus or inhibiting hepatitis B virus antigen. The invention also discloses application of the host factor RAB10 or the coding gene thereof as a drug target in screening drugs for resisting hepatitis B virus or inhibiting hepatitis B virus antigen. Researches show that RAB10 can significantly inhibit HBsAg expression, HBV DNA replication, HBV RNA transcription and HBs protein level, is expected to be used for developing a novel therapeutic drug for inhibiting hepatitis B virus surface antigen, and provides a new strategy for HBV functional cure.

The invention discloses a nano antibody targeting a hepatitis B core antigen as well as a coding gene and application thereof, and relates to the technical field of biological medicines. The nano antibody comprises an amino acid sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 5, and can be specifically combined with HBcAg. The invention also relates to a coding nucleic acid, an expression vector, a host cell and a preparation method of the nano antibody, and application of the nano antibody in preparation of anti-hepatitis B virus drugs and diagnostic reagents. Experiments show that the nano antibody has high affinity of targeting HBcAg, can combine and destroy hepatitis B virus nucleocapsid assembly and inhibit secretion of virus proteins such as HBsAg, HBeAg and the like, and thus has good anti-hepatitis B virus activity.

This invention provides an anti-S-HBs antibody and a method for using the same. [Solution] The present invention provides an antibody that binds to S-HBs, is cross-reactive to each of the HBV proteins of a specific sequence, and / or, when measured in vitro, has a neutralization IC50 value of ≤1 ng / ml against HBV genome D.

An anti-HBV agent containing a compound of Formula (I) or a salt thereof, where R1 is a phenyl group substituted with a group represented by -CN or R3-NH-CO- and an alkyl group having 1 to 6 carbon atoms, where R3 is an alkyl group having 1 to 10 carbon atoms or a group represented by the formula R4-(CH2)n1-, where R4 is CH2=CH-, a phenyl group, a cyclohexyl group, or a morpholino group, and n1 is an integer of 1 to 5; and R2 is a phenyl group substituted with a halogen.

The invention discloses a novel N4-acyl substituted-2 '-deoxy-2'-fluoro-4 '-azido cytidine derivative and pharmaceutical application thereof, the novel N4-acyl substituted-2'-deoxy-2 '-fluoro-4'-azido cytidine derivative has a structure of a general formula (b): in the formula, R1 is H, F or CH3; r2 = H, N3 or C2H; and R3 is C0-C10 straight chain or branched chain saturated and unsaturated alkane, C6-C12 aromatic alkane or C3-C6 heterocyclic alkane. N4-acyl substituted-2 '-deoxy-2'-fluoro-4 '-azide cytidine derivatives are synthesized by modifying the 4-amino group of a compound a, and the compounds have anti-hepatitis B virus and anti-tumor activity; the preparation method is feasible; the compound has a good application prospect when being applied to drugs for treating viruses and tumors.

The invention discloses an anti-hepatitis B virus drug metabolism kinetics prediction method based on a Transform model, and belongs to the crossing field of artificial intelligence and pharmacokinetics. The prediction method comprises the following steps: acquiring pharmacokinetic related data of three TFV prodrugs inside and outside a mouse, a beagle and a human body to form a data set; building liver cell PK and in-vivo mPBPK models, and developing liver injury mouse / human cell PK and mPBPK models on the basis; based on the experimental data set and the parameters of the cell PK and mPBPK models, constructing a data set for Transform model training; feature coding is carried out on a data set used for training, feature vectors are obtained through splicing, then the feature vectors are spliced with position codes to obtain input features to construct a Transform model, and the input features are input into the Transform model for training; and predicting the concentration of TFV-DP in human liver cells by using the trained Transform model, thereby accurately predicting the concentration of drugs in the human liver.

The present invention relates to the field of biomedicine and specifically discloses a composition containing clausenamide and its use in preparing a medicament for treating liver damage. The clausenamide-containing composition comprises clausenamide and an active compound; the active compound is selected from ergolactone and / or isosaxifragine. Studies have shown that the composition has an effect on resisting alcoholic liver damage and, in addition, an effect on resisting hepatitis B virus. Therefore, using the composition of the present invention as an active ingredient in preparing a medicament for treating liver damage and a medicament for resisting hepatitis B virus has important application value.

The present invention discloses the use of passutonic acid in the preparation of anti-hepatitis B virus drugs. Passutonic acid can inhibit the replication of hepatitis B virus, inhibit the production and replication of hepatitis B virus antigens, and inhibit the expression of hepatitis B virus mRNA and HBV transcription factors, and has a significant inhibitory effect on hepatitis B virus. It provides a new solution for the development of new anti-hepatitis B virus drugs. Moreover, as a traditional Chinese medicinal material, passutonic acid has abundant medicinal resources and low cost, and is of great significance to the research and development of new anti-hepatitis B virus drugs.

The invention belongs to the field of medicinal chemistry, and discloses PROTACs targeting hepatitis B virus as well as a preparation method and application of the PROTACs. The PROTACs of the targeted hepatitis B virus have a structure as shown in a formula I or a formula II, a ligand lenalidomide or pomalidomide of a Cerebron protein (CRBN) is selected as an E3 ligase ligand, a hepatitis B virus capsid protein inhibitor is coupled with E3 ligase through linkers of different types and different chain lengths, the PROTACs of the targeted hepatitis B virus are successfully prepared, and the PROTACs of the targeted hepatitis B virus can effectively target a target protein. The hepatitis B virus capsid protein inhibitor overcomes the defects that the hepatitis B virus capsid protein inhibitor is single in structure type, limited in drug effect exerting way and the like, has good inhibition and degradation activity on hepatitis B virus, and can be used as an anti-hepatitis B virus candidate drug for development and research.